Literature DB >> 22418245

Napsin A is an independent prognostic factor in surgically resected adenocarcinoma of the lung.

Jin Gu Lee1, Sewha Kim, Hyo Sup Shim.   

Abstract

INTRODUCTION: Napsin A is regarded as a marker of lung adenocarcinoma. However, no comprehensive analyses of napsin A-positive lung ADCs or the prognostic significance of napsin A expression have been reported to date.
METHODS: 110 primary lung adenocarcinoma cases were analyzed for clinicopathologic parameters, including overall survival, stage, histology, napsin A and TTF-1 expression, EGFR mutation, and ALK rearrangement.
RESULTS: Napsin A-positive adenocarcinomas were significantly more prevalent among tumors characterized as relatively small (p = 0.023), non-solid predominant (p < 0.001), non-mucinous/enteric (p < 0.001), positive for TTF-1 expression (p < 0.001), and positive for EGFR mutation (p = 0.001). Multivariate analysis of overall survival demonstrated that the absence of napsin A was an independent prognostic factor for reduced survival time (p = 0.002).
CONCLUSION: Clinicopathologic characteristics associated with napsin A-positive lung ADC are similar to and overlap with those of TTF-1-positive ADCs. The absence of napsin A is an independent poor prognostic factor in surgically resected adenocarcinoma. Further studies are necessary to determine the role of napsin A in the progression of lung adenocarcinoma.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22418245     DOI: 10.1016/j.lungcan.2012.02.013

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  13 in total

1.  The expression of TTF-1 and Napsin A in early-stage lung adenocarcinoma correlates with the results of surgical treatment.

Authors:  Yunfan Ma; Mengying Fan; Liang Dai; Xiaozheng Kang; Yiqiang Liu; Yu Sun; Wanpu Yan; Zhen Liang; Hongchao Xiong; Keneng Chen
Journal:  Tumour Biol       Date:  2015-05-16

2.  Lepidic and micropapillary growth pattern and expression of Napsin A can stratify patients of stage I lung adenocarcinoma into different prognostic subgroup.

Authors:  Xin Yang; Yu Liu; Fang Lian; Lei Guo; Peng Wen; Xiu-Yun Liu; Dong-Mei Lin
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

3.  Napsin A is a specific marker for ovarian clear cell adenocarcinoma.

Authors:  Yoriko Yamashita; Tetsuro Nagasaka; Aya Naiki-Ito; Shinya Sato; Shugo Suzuki; Shinya Toyokuni; Masafumi Ito; Satoru Takahashi
Journal:  Mod Pathol       Date:  2014-04-11       Impact factor: 7.842

4.  Napsin A Expression in Subtypes of Thyroid Tumors: Comparison with Lung Adenocarcinomas.

Authors:  Jianghua Wu; Yanhui Zhang; Tingting Ding; Runfen Cheng; Wenchen Gong; Yuhong Guo; Ye Luo; Yi Pan; Qiongli Zhai; Wei Sun; Dongmei Lin; Baocun Sun
Journal:  Endocr Pathol       Date:  2020-03       Impact factor: 3.943

5.  Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study.

Authors:  Dean A Fennell; Scott P Myrand; Tuan S Nguyen; David Ferry; Keith M Kerr; Perry Maxwell; Stephen D Moore; Carla Visseren-Grul; Mayukh Das; Marianne C Nicolson
Journal:  PLoS One       Date:  2014-09-24       Impact factor: 3.240

6.  Evaluation of epidermal growth factor receptor mutations and thyroid transcription factor-1 status in Turkish non-small cell lung carcinoma patients: A study of 600 cases from a single center.

Authors:  Malahat Musayeva; Serpil Dizbay Sak; Hilal Özakıncı; Şenay Boyacıgil; Öznur Coşkun
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-01-23       Impact factor: 0.332

Review 7.  Prognostic value of epidermal growth factor receptor mutations in resected non-small cell lung cancer: a systematic review with meta-analysis.

Authors:  Zhixuan Zhang; Ting Wang; Jun Zhang; Xiaohong Cai; Changchuan Pan; Yu Long; Jing Chen; Chengya Zhou; Xude Yin
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240

8.  Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations.

Authors:  Ruiguang Zhang; Yan Li; Xiu Nie; Xiaorong Dong; Gang Wu
Journal:  Onco Targets Ther       Date:  2016-01-18       Impact factor: 4.147

9.  [Clinicopathological and prognostic significance of a panel of tumor biomarkers in lung adenocarcinoma: a tissue microarray study].

Authors:  Xin Yang; Liyan Xue; Lei Guo; Peng Wen; Dongmei Lin
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-03

Review 10.  [Significance of immunohistochemical indicators in diagnosis and prognosis of 
squamous cell carcinoma and adenocarcinoma of lung].

Authors:  Yunfan Ma; Mengying Fan; Keneng Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.